Valuation: IXICO plc

Capitalization 14.45M 19.68M 16.72M 15.3M 26.95M 1.86B 27.18M 182M 70.77M 893M 73.85M 72.3M 3.08B P/E ratio 2026 *
-4.14x
P/E ratio 2027 * -5.1x
Enterprise value 4.85M 6.6M 5.61M 5.13M 9.04M 624M 9.12M 60.9M 23.74M 300M 24.77M 24.25M 1.03B EV / Sales 2026 *
0.64x
EV / Sales 2027 * 0.97x
Free-Float
69.39%
Yield 2026 *
-
Yield 2027 * -
1 day-0.38%
1 week-4.00%
Current month-4.00%
1 month-10.51%
3 months-35.61%
6 months-38.60%
Current year-43.83%
1 week 6.5
Extreme 6.5
7
1 month 6.5
Extreme 6.5
7.5
Current year 6.5
Extreme 6.5
12
1 year 6.5
Extreme 6.5
15
3 years 6.35
Extreme 6.35
21
5 years 6.35
Extreme 6.35
94.2
10 years 6.35
Extreme 6.35
127
Manager TitleAgeSince
Chief Executive Officer 53 2024-08-18
Director of Finance/CFO 50 2019-08-20
Chief Tech/Sci/R&D Officer - 2025-05-31
Director TitleAgeSince
Chairman 51 -
Director/Board Member 62 2023-10-04
Director/Board Member 50 2019-08-20
Change 5d. change 1-year change 3-years change Capi.($)
-0.38%-4.00%-28.65%-64.80% 19.68M
+0.12%+1.15%-15.82%-15.97% 43.39B
+1.65%+6.86%+36.13%+29.82% 34.7B
+1.64%-2.64%+243.82%+462.02% 30.15B
-2.37%+9.17%+12.53%-7.47% 29.83B
-2.02%-1.05%+30.59%+28.20% 28.46B
+0.78%+5.75% - - 14.82B
-3.52%+3.55%+129.04%+4,346.71% 14.48B
+0.85%+1.45%+128.29%+115.07% 12.51B
-1.45%+1.04%+4.13%-3.53% 12.29B
Average -0.45%+2.69%+60.01%+543.34% 22.06B
Weighted average by Cap. -0.26%+3.66%+61.64%+384.71%

Financials

2026 *2027 *
Net sales 7.51M 10.24M 8.7M 7.96M 14.02M 967M 14.14M 94.43M 36.81M 464M 38.41M 37.6M 1.6B 9.04M 12.32M 10.47M 9.58M 16.86M 1.16B 17.01M 114M 44.29M 559M 46.22M 45.25M 1.93B
Net income -2.38M -3.24M -2.76M -2.52M -4.44M -306M -4.48M -29.91M -11.66M -147M -12.17M -11.91M -508M -2.8M -3.82M -3.24M -2.97M -5.22M -360M -5.27M -35.2M -13.72M -173M -14.32M -14.02M -598M
Net Debt -9.6M -13.08M -11.11M -10.17M -17.91M -1.24B -18.07M -121M -47.03M -593M -49.08M -48.04M -2.05B -5.7M -7.77M -6.6M -6.04M -10.63M -734M -10.73M -71.64M -27.93M -352M -29.14M -28.53M -1.22B
Logo IXICO plc
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
Employees
79
Date Price Change Volume
26-05-11 6.600 p -0.38% 131,076
26-05-08 6.625 p -3.64% 296,903
26-05-07 6.875 p 0.00% 5,000
26-05-06 6.875 p 0.00% 2,600
26-05-05 6.875 p 0.00% 29,866
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0662GBP
Average target price
0.2600GBP
Spread / Average Target
+292.45%

Annual profits - Rate of surprise